TY - RPRT
KW - Opioid-Related Disorders -- drug therapy
KW - Buprenorphine -- Therapeutic Use
KW - Buprenorphine -- Adverse Effects
KW - Buprenorphine -- economics
KW - Opiate Substitution Treatment
KW - Cost-Benefit Analysis
KW - Comparative Effectiveness Research
KW - Practice Guidelines as Topic
KW - Treatment Outcome
KW - Canada
AU - Dave K. Marchand
AU - Calvin Young
AU - Hannah Loshak
A1 - 
AB - CADTH has previously reviewed the evidence for the use of buprenorphine formulations for the treatment of opioid use disorders (OUDs). One report was limited to pregnant populations, another was a qualitative review of patient preferences and perspectives, and the third was a summary of abstracts based on evidence available in 2017. The objective of the current report is to evaluate the comparative clinical effectiveness, safety, cost-effectiveness and evidencebased guidelines regarding various buprenorphine or combination product of buprenorphine with naloxone (BUP-NAL) formulations for the treatment of OUD.
BT - CADTH rapid response report: summary with critical appraisal,; Variation: Rapid response report (Canadian Agency for Drugs and Technologies in Health).
C4 - This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.
C5 - Grey Literature; Financing & Sustainability; Opioids & Substance Use
CY - Ottawa
JF - CADTH rapid response report: summary with critical appraisal,; Variation: Rapid response report (Canadian Agency for Drugs and Technologies in Health).
LA - English
M1 - Report
N2 - CADTH has previously reviewed the evidence for the use of buprenorphine formulations for the treatment of opioid use disorders (OUDs). One report was limited to pregnant populations, another was a qualitative review of patient preferences and perspectives, and the third was a summary of abstracts based on evidence available in 2017. The objective of the current report is to evaluate the comparative clinical effectiveness, safety, cost-effectiveness and evidencebased guidelines regarding various buprenorphine or combination product of buprenorphine with naloxone (BUP-NAL) formulations for the treatment of OUD.
PP - Ottawa
PY - 2019
RN - https://www.ncbi.nlm.nih.gov/books/NBK543511/
SN - Series 1922-8147; National Library: 101753641
T1 - Buprenorphine for opioid use disorder: A review of comparative clinical effectiveness, safety, cost-effectiveness, and guidelines. (CADTH rapid response report: summary with critical appraisal)
T2 - CADTH rapid response report: summary with critical appraisal,; Variation: Rapid response report (Canadian Agency for Drugs and Technologies in Health).
TI - Buprenorphine for opioid use disorder: A review of comparative clinical effectiveness, safety, cost-effectiveness, and guidelines. (CADTH rapid response report: summary with critical appraisal)
U1 - Grey Literature; Financing & Sustainability; Opioids & Substance Use
U4 - This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.
U5 - https://www.ncbi.nlm.nih.gov/books/NBK543511/
UR - https://www.ncbi.nlm.nih.gov/books/NBK543511/
VO - Series 1922-8147; National Library: 101753641
Y1 - 2019
ER -